Nxera Pharma Co., Ltd. (4565.T) Stock

4565.T logo

Nxera Pharma Co., Ltd.

4565.TJapan
Healthcare

Company profile

Nxera Pharma reported revenue of 29.62 billion JPY for fiscal year 2025, up 2.7% from fiscal year 2024. Japan was its largest region in fiscal year 2025, with 61% of revenue. Our analysis of its filings shows revenue growing from 12.77 billion JPY in fiscal year 2023 to 29.62 billion JPY in fiscal year 2025, 52.3% a year on average. Nxera Pharma reports about 314 full-time employees.

What stands out

  • It reported a net loss in each of its last 3 fiscal years, after a profit of 382.00 million JPY in fiscal year 2022; the loss widened from 4.84 billion JPY in fiscal year 2024 to 12.53 billion JPY in fiscal year 2025.
  • Its net profit margin over the last four reported quarters was -15.2%, against a median of 10.0% for 6 listed companies of similar size in its industry.
  • It spent 14.47 billion JPY on research and development in fiscal year 2025, 48.8% of its revenue.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Nxera Pharma Co., Ltd.

Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. It develops NBI-1117568, an muscarinic M4 agonist in phase 3 trial for schizophrenia, dementia and other neuropsychiatric disorders; ORX750, an OX2 agonist for narcolepsy, idiopathic hypersomnia, and other sleep-wake disorders; NBI-1117570, a dual muscarinic M1/M4 agonist; and HTL0039732, an EP4 antagonist immunotherapy drug. The company's products in phase 1 trial include PF-07054894, a CCR6 antagonist and NXE0033744, an EP4 agonist for inflammatory bowel disease; PF-07258669, a MC4 antagonist for anorexia; NBI-1117569, a muscarinic M4-preferring agonist, and NBI-1117567, a muscarinic M1 agonist for major central nervous system disorders; TMP-301, a mGlu5 NAM for substance use disorders; and NXE0048149, a GPR52 agonist for schizophrenia. Its products in preclinical trial comprise KY1051, a CXCR4 mAb for immuno-oncology; and NXE0027477, a GPR35 agonist for inflammatory bowel disease and GI disorders. The company also develops other discovery-stage drugs. It has strategic collaborations with Tempero Bio, Pharmenable Therapeutics, Antiverse, Sanofi, Cancer Research UK, Centessa Pharmaceuticals, Lilly, AbbVie, Genentech, Pfizer, Neurocrine Biosciences, Antiverse, and Novartis International AG. The company was formerly known as Sosei Group Corporation. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Minato, Japan.

Largest shareholders

  • Daisuke Gomi11.41 %11.41%
  • JIC Venture Growth Investments Co. Ltd.6.06%
  • Taiyo Pacific Partners LP4.69%
  • Asset Management One Co., Ltd.2.12%
  • Pfizer Inc.2.04%

Share of the company, as of September 25, 2026

Leadership

  • Christopher Cargill — Representative Executive Officer, President, CEO & Chairman, 41
  • Toshihiro Maeda — President of Nxera Pharma Japan & COO, 46
  • Patrik Foerch Ph.D. — Chief Scientific Officer, President of Nxera Pharma UK & Director
  • Hironoshin Nomura — Executive Officer & CFO, 42
  • Kieran Johnson F.C.A. — Executive Officer & Chief Accounting Officer, 56

How much revenue does Nxera Pharma make?

Nxera Pharma reported 29.62 billion JPY in revenue for fiscal year 2025, up 2.7% from 28.84 billion JPY in fiscal year 2024.

Where does Nxera Pharma make most of its revenue?

Japan: 61% of revenue by region in fiscal year 2025, followed by United States of America (16%).

What companies are similar to Nxera Pharma?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sumitomo Pharma Co., Ltd. (4506.T), Nippon Shinyaku Co., Ltd. (4516.T), Sawai Group Holdings Co., Ltd. (4887.T), Towa Pharmaceutical Co., Ltd. (4553.T).

Has Nxera Pharma made a profit in recent years?

Net income by fiscal year: FY2021, 1.02 billion JPY; FY2022, 382.00 million JPY; FY2023, a loss of 7.19 billion JPY; FY2024, a loss of 4.84 billion JPY; FY2025, a loss of 12.53 billion JPY. It reported a net loss in 3 of these 5 years.

How does Nxera Pharma's profit margin compare with similar companies?

Net profit margin over the last four reported quarters: Nxera Pharma, -15.2%; Sumitomo Pharma Co., Ltd. (4506.T), 9.4%; Nippon Shinyaku Co., Ltd. (4516.T), 17.5%; Sawai Group Holdings Co., Ltd. (4887.T), 0.0%; Towa Pharmaceutical Co., Ltd. (4553.T), 3.0%; Kissei Pharmaceutical Co., Ltd. (4547.T), 11.5%; Kaken Pharmaceutical Co., Ltd. (4521.T), 10.6%.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees314
FoundedJun 1990
IPO DateJul 29, 2004
IPO StatusPublic
HeadquartersMinato, Japan
FoundersShinichi Tamura
ExchangeTokyo
TimezoneAsia/Tokyo (JST)

Contact & Links

Address
Midtown East, Minato, 107-0052
Phone
81 3 5962 5718
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Nxera Pharma Co., Ltd. (4565.T)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/4565.T

LinkedInLinkedInXXYouTubeYouTube